Drugs anti-virals

J. Beigel (Baltimore, United States of America)

Source: Virtual Congress 2020 – Management

Session: Management
Session type: COVID-19
Number: 3638

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Beigel (Baltimore, United States of America). Drugs anti-virals. Virtual Congress 2020 – Management

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Management of COVID-19: Drugs anti-virals Source: ERS Course 2021 - COVID-19: State of the art Year: 2021
Drugs anti-inflammatories Source: Virtual Congress 2020 – Management Year: 2020
Anti-tuberculosis drugs Source: International Congress 2017 – State of the art session: "Respiratory infections" Year: 2017
Management of COVID-19: Drugs anti-inflammatories Source: ERS Course 2021 - COVID-19: State of the art Year: 2021
Prospects for new compounds tiosemikarbazonami class to create drugs with antituberculosis activity Source: International Congress 2014 – Tuberculosis: diagnosis Year: 2014
New and repurposed drugs Source: Eur Respir Monogr 2018; 82: 179-204 Year: 2018
Drug resistant pattern of antitubercular drugs in India Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008
Facts and perspectives in the development of new anti-TB drugs Source: Annual Congress 2008 - New insights into tuberculosis control Year: 2008
Availability of anti-tuberculosis drugs in Europe Source: Eur Respir J 2012; 40: 500-503 Year: 2012
Rational use of new TB drugs in the EU Source: Annual Congress 2012 - New guidelines in respiratory infections Year: 2012
Manifestations of hypersensitivity to anti-tuberculosis drugs Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018
Vaccines Source: Eur Respir Monogr 2014; 66: 36-59 Year: 2014
Antiviral drugs: which and when? Source: Annual Congress 2006 - Influenza: from avian flu to pandemia? Year: 2006
New anti-tuberculosis drugs and regimens: 2015 update Source: ERJ Open Res 2015; 1: 00010-2015 Year: 2015
Experimental justification choise to prevent hepatotoxic reactions to anti-TB drugs based on gene-phenotypic characteristics Source: International Congress 2019 – Tuberculosis: diagnosis Year: 2019
Novel anti-inflammatory agents Source: Annual Congress 2009 - Emerging trends in the therapy of COPD Year: 2009
Novel drug regimens against MDR-TB Source: International Congress 2016 – The problem of multidrug-resistant tuberculosis Year: 2016